1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > Cerebral Palsy - Pipeline Review, H1 2016

Cerebral Palsy - Pipeline Review, H1 2016

  • February 2016
  • -
  • Global Markets Direct
  • -
  • 46 pages

Cerebral Palsy - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Cerebral Palsy - Pipeline Review, H1 2016’, provides an overview of the Cerebral Palsy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cerebral Palsy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cerebral Palsy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cerebral Palsy
- The report reviews pipeline therapeutics for Cerebral Palsy by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Cerebral Palsy therapeutics and enlists all their major and minor projects
- The report assesses Cerebral Palsy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Cerebral Palsy

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Cerebral Palsy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cerebral Palsy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Cerebral Palsy - Pipeline Review, H1 2016
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Cerebral Palsy Overview 6
Therapeutics Development 7
Pipeline Products for Cerebral Palsy - Overview 7
Cerebral Palsy - Therapeutics under Development by Companies 8
Cerebral Palsy - Pipeline Products Glance 9
Late Stage Products 9
Early Stage Products 10
Cerebral Palsy - Products under Development by Companies 11
Cerebral Palsy - Companies Involved in Therapeutics Development 12
Allergan Plc 12
Cell Cure Neurosciences, Ltd. 13
Cellular Biomedicine Group, Inc. 14
CHA Bio and Diostech Co., Ltd. 15
Neuralstem, Inc. 16
Cerebral Palsy - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Target 18
Assessment by Mechanism of Action 20
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
Cyto-012 - Drug Profile 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
NeurArrest - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
NSI-566 - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
onabotulinumtoxin A - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
Stem Cell Therapy for Cerebral Palsy - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
Stem Cell Therapy for Cerebral Palsy and Systemic Lupus Erythematosus - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
Cerebral Palsy - Recent Pipeline Updates 34
Cerebral Palsy - Dormant Projects 44
Appendix 45
Methodology 45
Coverage 45
Secondary Research 45
Primary Research 45
Expert Panel Validation 45
Contact Us 45
Disclaimer 46

List of Tables
Number of Products under Development for Cerebral Palsy, H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Late Stage Development, H1 2016 9
Comparative Analysis by Early Stage Development, H1 2016 10
Products under Development by Companies, H1 2016 11
Cerebral Palsy - Pipeline by Allergan Plc, H1 2016 12
Cerebral Palsy - Pipeline by Cell Cure Neurosciences, Ltd., H1 2016 13
Cerebral Palsy - Pipeline by Cellular Biomedicine Group, Inc., H1 2016 14
Cerebral Palsy - Pipeline by CHA Bio and Diostech Co., Ltd., H1 2016 15
Cerebral Palsy - Pipeline by Neuralstem, Inc., H1 2016 16
Assessment by Monotherapy Products, H1 2016 17
Number of Products by Stage and Target, H1 2016 19
Number of Products by Stage and Mechanism of Action, H1 2016 20
Number of Products by Stage and Route of Administration, H1 2016 22
Number of Products by Stage and Molecule Type, H1 2016 24
Cerebral Palsy Therapeutics - Recent Pipeline Updates, H1 2016 34
Cerebral Palsy - Dormant Projects, H1 2016 44

List of Figures
Number of Products under Development for Cerebral Palsy, H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Early Stage Products, H1 2016 10
Assessment by Monotherapy Products, H1 2016 17
Number of Products by Targets, H1 2016 18
Number of Products by Stage and Targets, H1 2016 18
Number of Products by Routes of Administration, H1 2016 21
Number of Products by Stage and Routes of Administration, H1 2016 21
Number of Products by Molecule Types, H1 2016 23
Number of Products by Stage and Molecule Types, H1 2016 23

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Pipeline Review, H2 2016

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Metabotropic Glutamate Receptor 5 (GPRC1E or MGLUR5 or GRM5) - Pipeline Review, ...

Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Pipeline Review, H2 2016

Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • October 2016
  • by Global Markets Direct

Superoxide Dismutase [Cu-Zn] (Superoxide Dismutase 1 or Epididymis Secretory Protein Li 44 or SOD1 or EC 1.15.1.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Superoxide Dismutase ...

Multiple Sclerosis - Pipeline Review, H2 2016

Multiple Sclerosis - Pipeline Review, H2 2016

  • $ 2500
  • Company report
  • December 2016
  • by Global Markets Direct

Multiple Sclerosis - Pipeline Review, H2 2016 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Multiple Sclerosis – Pipeline Review, H2 2016, provides an ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.